You are here

TRIANGLE THERAPEUTICS INC.

Company Information
Address
6162 BRISTOL PKWY
CULVER CITY, CA 90230-6604
United States


http://trethera.com

Information

UEI: N/A

# of Employees: 1


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)

    Amount: $304,461.00

    PROJECT SUMMARY Acute disseminated encephalomyelitis (ADEM) is an acute autoimmune disease that can present with fever and ataxia as well as loss of consciousness and coma. ADEM largely affects childr ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  2. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Systemic Lupus Erythematosus

    Amount: $305,135.00

    PROJECT SUMMARY Lupus is a chronic, systemic autoimmune disease in which cells of the immune system attack organ systems throughout the body including the kidneys, brain, and lungs and that presents h ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  3. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Crohn's disease

    Amount: $395,119.00

    PROJECT SUMMARY Crohn’s disease (CD) is a chronic autoimmune disease in which cells of the immune system attack gut tissue leading to diarrhea, fatigue, pain, and weight loss. CD affects up to one m ...

    STTRPhase I2023Department of Health and Human Services National Institutes of Health
  4. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleotide Salvage Pathway to Treat Underserved Tumor Types

    Amount: $1,349,805.00

    PROJECT SUMMARY Trethera, a clinical stage biopharmaceutical company, has developed a small molecule drug, TRE-515, to target the nucleoside salvage pathway via a key rate-limiting enzyme, deoxycytidi ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  5. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis

    Amount: $368,195.00

    PROJECT SUMMARY Optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments accelerate recovery of ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government